Visionary Holdings partners with Yike for medical aesthetics research

NEW YORK - Visionary Holdings Inc. (NASDAQ:GV) announced Wednesday it has entered into a strategic partnership with Jiangsu Yike Regenerative Medicine to collaborate on research and development in cellular rejuvenation and aesthetic treatment. The announcement comes as GV’s stock trades at $2.19, showing an 11.74% gain over the past week despite a challenging year that saw a 73% decline over the last six months. With a market capitalization of just $6.17 million, InvestingPro data suggests the company is currently undervalued.

Under the agreement, Yike will lead and fund the research projects while securing related intellectual property. GV will have the option to acquire or license the rights based on market potential, with consideration paid in cash or GV shares. According to InvestingPro analysis, GV’s financial health score is currently rated as WEAK, with revenue of $7.77 million in the last twelve months showing a 32.53% decline.

The collaboration will focus on three core areas: cell activation and telomerase homeostasis, smart delivery systems with personalized solutions, and stem cell and immune cell applications for aesthetic treatments.

Dr. Zhenyu Ju, Chief Scientist of Yike and Dean of the Institute of Aging and Regenerative Medicine at Jinan University, will lead the research team. Dr. Ju is a recipient of China’s National Science Fund for Distinguished Young Scholars.

The partnership aligns with GV’s recent establishment of Visionary Health Technology Group Limited in Hong Kong as its Asia-Pacific headquarters in June 2025.

"This partnership with Yike is an essential part of GV’s China strategy and a key milestone in our overall development," said GV CEO Jay Lee in the press release statement.

According to industry research cited in the announcement, China’s medical aesthetics market exceeded RMB 200 billion (approximately $28 billion) in 2023 and is projected to surpass RMB 500 billion (approximately $70 billion) by 2030.

Jiangsu Yike Regenerative Medicine specializes in regenerative medicine and precision anti-aging technologies, operating across multiple platforms including genetic engineering and stem cell research.

The announcement represents Visionary Holdings’ strategic move into the consumption healthcare sector, specifically targeting the medical aesthetics industry. While the company’s current price-to-book ratio stands at 0.46, InvestingPro subscribers have access to over 30 additional financial metrics and exclusive insights to better evaluate this strategic pivot. Discover more detailed analysis and investment opportunities in the medical aesthetics sector with an InvestingPro subscription.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.